Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics, Inc. (NASDAQ: KDNY) announced participation in two upcoming virtual investor conferences. Management will engage in a live fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 5:00 pm EDT. Additionally, there will be an on-demand fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference starting September 13 at 7:00 am EDT. The company will also hold 1x1 meetings between September 9 and 15. Archived webcasts will be available on their website for 90 days.

SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences:

• Morgan Stanley 19^th Annual Global Healthcare Conference – live fireside chat on Thursday, September 9^th at 5:00 pm EDT
  

• H.C. Wainwright 23^rd Annual Global Investment Conference – fireside chat will be available on-demand beginning Monday, September 13^th at 7:00 am EDT
  

Chinook will also participate in 1x1 meetings through Morgan Stanley and H.C. Wainwright on Thursday, September 9^th – Wednesday, September 15^th.

To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

FAQ

When is Chinook Therapeutics participating in the Morgan Stanley Annual Global Healthcare Conference?

Chinook Therapeutics will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 5:00 pm EDT.

What is the date of the H.C. Wainwright Annual Global Investment Conference participation?

Chinook Therapeutics will be featured in an on-demand fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference starting September 13, 2021, at 7:00 am EDT.

How can I access the webcasts of Chinook Therapeutics' presentations?

You can access the live webcasts and archived recordings of Chinook Therapeutics' presentations on their Investors section of the website.

What are the dates for 1x1 meetings held by Chinook Therapeutics?

Chinook Therapeutics will hold 1x1 meetings from September 9 to September 15, 2021.